128 related articles for article (PubMed ID: 33007330)
1. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
Shi Y; Ma Z; Cheng Q; Wu Y; Parris AB; Kong L; Yang X
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118877. PubMed ID: 33007330
[TBL] [Abstract][Full Text] [Related]
2. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
3. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
Yang Y; Chan JY; Temiz NA; Yee D
Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
[TBL] [Abstract][Full Text] [Related]
4. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
[TBL] [Abstract][Full Text] [Related]
5. Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.
Meyer K; Albaugh B; Schoenike B; Roopra A
Mol Cell Biol; 2015 Sep; 35(17):2991-3004. PubMed ID: 26100015
[TBL] [Abstract][Full Text] [Related]
6. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
[TBL] [Abstract][Full Text] [Related]
7. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
8. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
[TBL] [Abstract][Full Text] [Related]
10. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
11. Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
Tandon M; Chen Z; Othman AH; Pratap J
Oncogene; 2016 Sep; 35(36):4730-40. PubMed ID: 26804175
[TBL] [Abstract][Full Text] [Related]
12. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
13. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
14. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1.
Cesarone G; Edupuganti OP; Chen CP; Wickstrom E
Bioconjug Chem; 2007; 18(6):1831-40. PubMed ID: 17922544
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells.
Cesarone G; Garofalo C; Abrams MT; Igoucheva O; Alexeev V; Yoon K; Surmacz E; Wickstrom E
J Cell Biochem; 2006 May; 98(2):440-50. PubMed ID: 16440325
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
17. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
18. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
19. The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
Bronsveld HK; De Bruin ML; Wesseling J; Sanders J; Hofland I; Jensen V; Bazelier MT; Ter Braak B; de Boer A; Vestergaard P; Schmidt MK
BMC Cancer; 2018 Feb; 18(1):224. PubMed ID: 29486734
[TBL] [Abstract][Full Text] [Related]
20. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
de Miranda LBL; Lima K; Coelho-Silva JL; Traina F; Kobayashi SS; Machado-Neto JA
Sci Rep; 2022 Oct; 12(1):17092. PubMed ID: 36224313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
